- Anti-microbial technology company Byotrol first-half losses narrowed, but the company said it expected its US division to generate a loss owing to administrative delays to EPA approval of new product variants.

'The board remains confident in the outlook for full year, except for the US, which is expected to make a loss due to administrative delays to EPA approval of new product variants, which we now expect to be satisfactorily resolved in Q1 2019, the company said.

For six months ended 30 September 2018, losses narrowed to £0.581m from £0.805m a year earlier, and sales were up 55% to £0.1.44m.

Operating costs weighed on performance, however, increasing by 32%, largely reflecting one-off acquisition costs of £0.12m and investment in sales and marketing and research and development, the company said.

'We are pleased with solid progress in the first half and delighted to now have Medimark as part of our Group. It is a transformational acquisition and the two teams are already working well together. We look forward to the full contribution from Medimark in the second half and to the numerous benefits that further co-operation and integration will bring, said David Traynor, Chief Executive of Byotrol.

At 9:01am: [LON:BYOT] Byotrol PLC share price was -0.05p at 1.8p

Story provided by